Low angle light scattering analysis: A novel quantitative method for functional characterization of human and murine platelet receptors

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 7, 2012, Pages 1253-1262

  Mindukshev, Igor ^a,b   Gambaryan, Stepan ^a,b   Kehrer, Linda ^a   Schuetz, Claudia ^a   Kobsar, Anna ^a   Rukoyatkina, Natalia ^a,b   Nikolaev, Viacheslav O ^c   Krivchenko, Alexander ^b   Watson, Steve P ^d   Walter, Ulrich ^a   Geiger, Joerg ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Aggregation; P2X1 receptor; P2Y receptors; Platelet

Indexed keywords

THROMBOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIGHT SCATTERING; LOW ANGLE LIGHT SCATTERING; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; BLOOD PLATELETS; COLLAGEN; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIGHT; MICE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PLATELET-RICH PLASMA; RECEPTORS, PURINERGIC P2; SCATTERING, RADIATION; THROMBOXANE A2;

EID: 84867748954     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.817     Document Type: Article

References (37)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-34.
2. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007;100:1673-85.
3. Gawaz M. Platelets in the onset of atherosclerosis. Blood Cells Mol Dis 2006;36:206-10.
4. Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol 2010;42:1762-6.
5. Trip MD, Cats VM, Van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.
6. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009;15:665-73.
7. Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovasc Revasc Med 2011;12:312-22.
8. Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963;168:178-95.
9. Spurej E, Glatter O, Pfeiler G. Shape change of human blood platelets: reliable and fast detection by quasi-elastic light scattering. Experientia 1992;48:71-9.
10. Abela GS, Huang R, Ma H, Prieto AR, Lei M, Schmaier AH, et al. Laser-light scattering, a new method for continuous monitoring of platelet activation in circulating fluid. J Lab Clin Med 2003;141:50-7.
11. Ingerman-Wojenski C, Smith JB, Silver MJ. Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets. J Lab Clin Med 1983;101:44-52.
12. (12) receptor inhibition by the PFA-100 system. Platelets 2010;21:112-6.
13. Gambaryan S, Geiger J, Schwarz UR, Butt E, Begonja A, Obergfell A, et al. Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood 2004;103:2593-600.
14. Gruner S, Prostredna M, Aktas B, Moers A, Schulte V, Krieg T, et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced α2β1 levels or concomitant aspirin therapy. Circulation 2004;110:2946-51.
15. Latimer P. Blood platelet aggregometer: predicted effects of aggregation, photometer geometry, and multiple scattering. Appl Opt 1983;22:1136-43.
16. Hulst VD. Light scattering by small particles. New York: John Willey & Sons, 1957.
17. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998;273:2024-9.
18. Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost 2005;31:150-61.
19. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006;46:277-300.
20. 12 receptor in platelet activation. Platelets 2011;22:54-8.
21. 1 receptor is necessary for adenosine 5'-diphosphateinduced platelet aggregation. Blood 1998;92:152-9.
22. 1-deficient mice. Nat Med 1999;5:1199-202.
23. (1) receptor-null mice. J Clin Invest 1999;104:1731-7.
24. 12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003;112:398-406.
25. (1) receptors: evidence for separate receptors (stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000;131:108-14.
26. +) in the human platelet. J Thromb Haemost 2007;5:910-7.
27. 1receptors in platelet activation. Platelets 2004;15:131-44.
28. 1 receptors. J Thromb Haemost 2003;1:2626-35.
29. + influx on functional responses in human platelets. Thromb Haemost 2002;88:495-502.
30. 1 receptor at nanomolar ATP concentrations. J Gen Physiol 2003;121:451-61.
31. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002;82:1013-67.
32. 12, TxA2 and GPVI receptors. Hamostaseologie 2010;30:29-38.
33. Beigel R, Hod H, Fefer P, Asher E, Novikov I, Shenkman B, et al. Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 107:339-42.
34. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - a meta-analysis. Int J Cardiol 2008;128:166-71.
35. Schuhmann CG, Sohn HY, Nagel J, Spannagl M, Klauss V, Krotz F. Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy - initial experiences. Platelets 2009;20:498-504.
36. Frelinger AL, 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009;120:2586-96.
37. 12 receptor: no active metabolite, no party. Nat Rev Cardiol 2009;6:271-2.